22nd Century submits a “Modified Risk Tobacco Products” application to the FDA for the Company’s BRAND A proprietary Very Low Nicotine cigarettes.
22nd Century Group launches MAGIC Very Low Nicotine cigarettes, in Europe.
22nd Century purchases strategically important intellectual property (both patents and patent applications, including TRANSCRIPTION FACTOR Technology) from National Research Council of Canada.
22nd Century and British American Tobacco (BAT) enter into a worldwide research license agreement.
22nd Century enters into a 3-year R&D agreement with the University of Virginia.
22nd Century receives FDA clearance for an Investigational New Drug (IND) Application for X-22. 22nd Century licenses to its subsidiary, Heracles Pharmaceuticals, all rights to X-22.
NARA Institute of Science & Technology assigns to 22nd Century all patents that NARA had previously exclusively licensed to 22nd Century.
22nd Century funds 3-year R&D project at National Research Council (NRC), Plant Biotechnology Unit, Saskatoon Canada; obtains exclusive worldwide license from NRC for MPO genes and TRANSCRIPTION FACTOR Technology.
22nd Century funds two 4-year R&D projects at North Carolina State University.
22nd Century funds 4-year R&D project at NARA Institute of Science & Technology in Japan; obtains exclusive worldwide license from NARA for NBB1, A622 and MPO genes.
22nd Century Limited is founded to fund a 5-year R&D project at North Carolina State University (NCSU) on nicotine biosynthesis in tobacco; obtains exclusive worldwide license from NCSU for QPT genes and other technologies.